In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Senseonics nets $149.3mm via FOPO

Executive Summary

Senseonics Holdings Inc. (developer of the Eversense implantable continuous glucose monitoring system for diabetics) netted $149.3mm through the follow-on offering of 38.1mm common shares (including full exercise of the overallotment) at $3.9263 each. The company will use the funds to commercialize Eversense in the US and for R&D of future configurations of the device.
Deal Industry
  • Biotechnology
  • Medical Devices
  • Medical Devices
    • Implantable Devices
    • Monitoring Equipment & Devices
  • In Vitro Diagnostics
    • Biosensors
    • Glucose Testing
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies